CHU Pontchaillou, Université Rennes 1, Service des maladies de l’appareil digestif, 2 rue Henri Le Guilloux 35033 Cedex 09
Due to the increased incidence of digestive neuroendocrine tumors (NETs) and the high proportion of intestinal primary tumors contributing to increase the frequency of carcinoid syndrome, on the one hand, and the improvement of survival of metastatic patients who are exposed longer and to several types of therapies, on the other hand, maintaining or even improving the quality of life of patients with digestive NETs becomes a major objective in the management of these patients. However, few studies have focused on quality of life assessment and evaluation tools are not consistent across studies. In these studies, patients with NET reported worse health-related quality of life compared to the general population, even in the absence of carcinoid syndrome or tumor in place. The main available treatments that have been shown to be effective in tumor control do not result in a change in overall quality of life but may improve (fatigue, pain, insomnia with octreotide) or worsen (diarrhea with sunitinib). Peptide receptor radionuclide therapy with 177Lu-Dotatate is the only anti-tumor treatment that have demonstrated to date in a phase III trial a significant improvement in both survival and quality of life of patients.
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License